GIUGLIANO, FEDERICA
GIUGLIANO, FEDERICA
Dipartimento di Oncologia ed Emato-Oncologia
Radioligand Therapy in Metastatic Breast Cancer: Harnessing Precision Oncology
2025 F. Giugliano, E. Giordano, L. Gilardi, B.T. Salimbeni, P. Zagami, A. Esposito, A. Marra, D. Trapani, P.P.M. Berton Giachetti, B. Malagutti, T. Henry, D. Deandreis, G. Curigliano, F. Ceci, C. Criscitiello
Overcoming Resistance to CDK4/6 inhibitors in Hormone Receptor positive, HER2 negative breast cancer: Innovative Combinations and Emerging Strategies
2025 F. Giugliano, C. De Angelis, B. Pistilli, G. Viale, G. Bianchini, M. Giuliano, L. Malorni, B. Taurelli Salimbeni, A. Esposito, A. Giordano, T.A. Yap, G. Curigliano, C. Criscitiello
Characteristics and clinical outcomes of breast cancer in young BRCA carriers according to tumor histology
2024 E. Agostinetto, M. Bruzzone, A. Hamy, H.J. Kim, C. Chiodi, R. Bernstein-Molho, S. Linn, K. Pogoda, E. Carrasco, F. Derouane, J. Bajpai, G. Nader-Marta, N. Lopetegui-Lia, A.H. Partridge, L. Cortesi, C. Rousset-Jablonski, F. Giugliano, T. Renaud, A. Ferrari, S. Paluch-Shimon, R. Fruscio, W. Cui, S.M. Wong, C. Vernieri, K.J. Ruddy, M.V. Dieci, A. Matikas, M. Rozenblit, D. Aguilar Y Mendez, L. De Marchis, R. Borea, F. Puglisi, M. Pistelli, J. Kufel-Grabowska, R. Di Rocco, E. Mariamidze, F. Atzori, H.R. Kourie, L. Popovic, E. de Azambuja, E. Blondeaux, M. Lambertini
PARP Inhibitors for Breast Cancer Treatment
2024 S. Morganti, A. Marra, C. De Angelis, A. Toss, L. Licata, F. Giugliano, B. Taurelli Salimbeni, P.P.M. Berton Giachetti, A. Esposito, A. Giordano, G. Bianchini, E. Garber Judy, G. Curigliano, F. Lynce, C. Criscitiello
Effect of age on safety and efficacy of novel cancer drugs investigated in early-phase clinical trials
2024 E. Nicolò, S. Gandini, F. Giugliano, J. Uliano, O. D'Ecclesiis, S. Morganti, E. Ferraro, D. Trapani, P. Tarantino, P. Zagami, L. Boldrini, I. Caramella, A. Carnevale Schianca, M. Cristofanilli, M.A. Locatelli, A. Esposito, C. Belli, I. Minchella, C. Criscitiello, A. Marra, G. Curigliano
Immune-Related Adverse Event Likelihood Score Identifies “Pure” IRAEs Strongly Associated With Outcome in a Phase I-II Trial Population
2024 L. Mazzarella, F. Giugliano, E. Nicolo, A. Esposito, E. Crimini, G. Tini, J. Uliano, C. Corti, P. D'Amico, P.T. Aliaga, C. Valenza, M. Repetto, G. Antonarelli, L. Ascione, G. Vivanet, P.P.M. Berton Giachetti, I. Minchella, C. Belli, M. Locatelli, C. Criscitiello, G. Curigliano
Characteristics, treatment patterns and survival of patients with high-risk early hormone receptor-positive breast cancer in French real-world settings: an exploratory study of the CANTO cohort
2024 F. Giugliano, A. Bertaut, J. Blanc, A.-. Martin, C. Gaudin, M. Fournier, A. Kieffer, B. Sauterey, C. Levy, M. Campone, C. Tarpin, F. Lerebours, M.-. Mouret-Reynier, G. Curigliano, F. Andre, B. Pistilli, E. Rassy
Evolution of biological features of invasive lobular breast cancer: Comparison between primary tumour and metastases
2023 P. Trillo, J. Sandoval, D. Trapani, E. Nicolò, P. Zagami, F. Giugliano, P. Tarantino, G. Vivanet, L. Ascione, A. Friedlaender, A. Esposito, C. Criscitiello, G. Curigliano
Unlocking the Resistance to Anti-HER2 Treatments in Breast Cancer: The Issue of HER2 Spatial Distribution
2023 F. Giugliano, A. Carnevale Schianca, C. Corti, M. Ivanova, N. Bianco, S. Dellapasqua, C. Criscitiello, N. Fusco, G. Curigliano, E. Munzone
HER2-Low Breast Cancer: a New Subtype?
2023 C. Corti, F. Giugliano, E. Nicolò, P. Tarantino, C. Criscitiello, G. Curigliano
Baseline Tumor Size as Prognostic Index in Patients With Advanced Solid Tumors Receiving Experimental Targeted Agents
2023 E. Nicolò, P. Tarantino, O. D'Ecclesiis, G. Antonarelli, L. Boscolo Bielo, A. Marra, S. Gandini, E. Crimini, F. Giugliano, P. Zagami, C. Corti, D. Trapani, S. Morganti, C. Criscitiello, M. Locatelli, C. Belli, A. Esposito, I. Minchella, M. Cristofanilli, S.M. Tolaney, G. Curigliano
Breast Cancer with Brain Metastasis: Molecular Insights and Clinical Management
2023 M. Ivanova, F.M. Porta, F. Giugliano, C. Frascarelli, E. Sajjadi, K. Venetis, G. Cursano, G. Mazzarol, E. GUERINI ROCCO, G. Curigliano, C. Criscitiello, N. Fusco
Clinical utility of genomic signatures for the management of early and metastatic triple-negative breast cancer
2023 G. Castellano, F. Giugliano, G. Curigliano, A. Marra
HER2-low expression in breast oncology: treatment implications in the smart chemotherapy era
2023 F. Giugliano, G. Curigliano, P. Tarantino
Safety of mRNA-COVID-19 Vaccines in Patients With Thoracic Cancers
2023 G. Spitaleri, P. Trillo Aliaga, C. Catania, E.D. Signore, I. Attili, C. Santoro, F. Giugliano, P.P.M. Berton Giachetti, G. Curigliano, A. Passaro, F. De Marinis
Clinicopathological features and survival outcomes of luminal-like breast tumors with estrogen receptor loss at metastatic recurrence: A case-control study
2023 S. Morganti, A. Marra, S. Gandini, L. Ascione, M. Ivanova, K. Venetis, E. Sajjadi, P. Zagami, F. Giugliano, B. Taurelli Salimbeni, P.P.M. Berton Giachetti, C. Corti, E. De Camilli, G. Curigliano, N. Fusco, C. Criscitiello
Fast Mimicking Diets and Other Innovative Nutritional Interventions to Treat Patients with Breast Cancer
2023 F. Giugliano, L. Boldrini, J. Uliano, E. Crimini, I. Minchella, G. Curigliano
SARS-CoV-2 vaccine in patients with thymic epithelial tumours with and without active or pre-existing autoimmune disorders: Brief report of a TYME network safety analysis
2022 F. Giugliano, P.A. Zucali, G. Galli, Z. Ballatore, C. Corti, P.T. Aliaga, J. Uliano, G. Vivanet, G. Curigliano, F. Conforti, P. Queirolo, R. Berardi, S. Manglaviti, G. Apollonio, M. Perrino, F. Borea, F. D'Antonio, M.C. Garassino, T. De Pas
Postneoadjuvant treatment for triple-negative breast cancer
2022 D. Trapani, E. Ferraro, F. Giugliano, L. Boscolo Bielo, G. Curigliano, H.J. Burstein
Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives
2022 E. Nicolò, F. Giugliano, L. Ascione, P. Tarantino, C. Corti, S.M. Tolaney, M. Cristofanilli, G. Curigliano